Expression TGM2 and BNIP3 have prognostic significance in laryngeal cancer patients receiving surgery and postoperative radiotherapy: A retrospective study

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Jin, Ting ^a   Lin, Huan Xin ^b   Lin, Hui ^b   Guo, Li Bing ^c   Ge, Nan ^b   Cai, Xiu Yu ^b   Sun, Rui ^b   Chen, Wen Kuan ^b   Li, Qiu Li ^b   Hu, Wei Han ^b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c GUANGDONG SECOND PROVINCIAL GENERAL HOSPITAL   (China)

Author keywords

BNIP3; Laryngeal cancer; Postoperative radiotherapy; Prognosis; TGM2

Indexed keywords

PROTEIN BNIP3; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; BNIP3 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BNIP3 GENE; CANCER RADIOTHERAPY; CANCER STAGING; CERVICAL LYMPH NODE; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNGECTOMY; LARYNX SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; OVERALL SURVIVAL; POSTOPERATIVE RADIOTHERAPY; PREDICTIVE VALUE; PROGNOSIS; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2 GENE; SURVIVAL RATE; ADJUVANT THERAPY; EVALUATION; LARYNX TUMOR; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; POSTOPERATIVE CARE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; GTP-BINDING PROTEINS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TRANSGLUTAMINASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84859042870     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-64     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. Bruick RK. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 2000, 97:9082-9087. 10.1073/pnas.97.16.9082, 16825, 10922063.
3. Guo K, Searfoss G, Krolikowski D, Pagnoni M, Franks C, Clark K, Yu KT, Jaye M, Ivashchenko Y. Hypoxia induces the expression of the pro-apoptotic gene BNIP3. Cell Death Differ 2001, 8:367-376. 10.1038/sj.cdd.4400810, 11550088.
4. Regula KM, Ens K, Kirshenbaum LA. Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ Res 2002, 91:226-231. 10.1161/01.RES.0000029232.42227.16, 12169648.
5. Okami J, Simeone DM, Logsdon CD. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. Cancer Res 2004, 64:5338-5346. 10.1158/0008-5472.CAN-04-0089, 15289340.
6. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA, Friess H. Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 2005, 24:4421-4432. 10.1038/sj.onc.1208642, 15856026.
7. Tang H, Liu YJ, Liu M, Li X. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP. Anticancer Drugs 2007, 18:633-639. 10.1097/CAD.0b013e3280200428, 17762391.
8. Folk JE. Transglutaminases. Annu Rev Biochem 1980, 49:517-531. 10.1146/annurev.bi.49.070180.002505, 6105840.
9. Jang GY, Jeon JH, Cho SY, Shin DM, Kim CW, Jeong EM, Bae HC, Kim TW, Lee SH, Choi Y, Lee DS, Park SC, Kim IG. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene 2010, 29:356-367. 10.1038/onc.2009.342, 19838207.
10. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004, 10:8068-8076. 10.1158/1078-0432.CCR-04-1107, 15585642.
11. Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, Kim SY. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem 2004, 279:53725-53735. 10.1074/jbc.M407627200, 15471861.
12. Thompson L. World Health Organization classification of tumours: pathology and genetics of head and neck tumours. Ear Nose Throat J 2006, 85:74.
13. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005, 11:7658-7663. 10.1158/1078-0432.CCR-05-0460, 16278385.
14. Bastit L, Blot E, Debourdeau P, Menard J, Bastit P, Le Fur R. Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys 2001, 49(1):139-146. 10.1016/S0360-3016(00)01376-6, 11163507.
15. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck node metastases as a prognostic factor. Cancer 1993, 73(1):187-190.
16. Leibel SA, Scott CB, Mohiuddin M, Marcial VA, Coia LR, Davis LW, Fuks Z. The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. Int J Radiat Oncol Biol Phys 1991, 21(3):549-556. 10.1016/0360-3016(91)90669-U, 1869453.
17. Richard JM, Sancho-Garnier H, Micheau C, Saravane D, Cachin Y. Prognostic factors in cervical lymph node metastasis in upper respiratory and digestive tract carcinomas: study of 1713 cases during a 15-year period. Laryngoscope 1987, 97(1):97-101.
18. Stell PM. Prognosis in laryngeal carcinoma: tumor factors. Clin Otolaryngol 1990, 15(1):69-81. 10.1111/j.1365-2273.1990.tb00436.x, 2323084.
19. Hoffstetter S, Malissard L, N'Guyen TD, Panis X, Jung GM, Bachaud JM, Prevost B, Quint R, Chaplain G, Eschwège F, Rambert P, Fleury-Touzeau F. Results of postoperative cervical node irradiation in carcinoma of the pharyngo-larynx. A study of the cooperative group of radiotherapist. Bull Cancer Radiother 1996, 83(2):86-89.
20. van den Bogaert W, Ostyn F, van der Schueren E. The different clinical presentation, behaviour and prognosis of carcinomas originating in the epilarynx and lower supraglottis. Radiother Oncol 1983, 1(2):117-131. 10.1016/S0167-8140(83)80015-2, 6680217.
21. Wall TJ, Peters LJ, Brown BW, Oswald MJ, Milas L. Relationship between lymph nodal status and primary tumor control probability in tumors of the supraglottic larynx. Int J Radiat Oncol Biol Phys 1985, 11(11):1895-1902. 10.1016/0360-3016(85)90269-X, 4055449.
22. Kramer S, Gelber RD, Snow JB, Marcial VA, Lowry LD, Davis LW, Chandler R. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of the study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg 1987, 10(1):19-30. 10.1002/hed.2890100105, 3449477.
23. Nguyen TD, Malissard L, Théobald S, Eschwège F, Panis X, Bachaud JM, Rambert P, Chaplain G, Quint R. Advanced carcinoma of the larynx: results of surgery and radiotherapy without induction chemotherapy (1980-1985): a multivariate analysis. Int J Radiat Oncol Biol Phys 1996, 5(5):1013-1018.
24. Wolf GT, Hong WK, Fisher SG. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with laryngeal cancer. N Engl J Med 1991, 324(24):1685-1690.
25. Leibel SA, Fuks Z. The impact of local tumor control on the outcome of human cancer. Current topics in clinical radiobiology of tumors 1993, 113-127. Berlin: Springer-Ve rlag, Beck-B ornholdt HP.
26. Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 2007, 26:2459-2470. 10.1038/sj.onc.1210035, 17043648.
27. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal BB, Mehta K. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res 2006, 66:8788-8795. 10.1158/0008-5472.CAN-06-1457, 16951195.
28. Dardik R, Inbal A. Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF. Exp Cell Res 2006, 312:2973-2982. 10.1016/j.yexcr.2006.05.019, 16914140.
29. Kim DS, Park KS, Jeong KC, Lee BI, Lee CH, Kim SY. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Cancer Lett 2009, 273:243-249. 10.1016/j.canlet.2008.08.015, 18804908.
30. Barnes RN, Bungay PJ, Elliott BM, Walton PL, Griffin M. Alterations in the distribution and activity of transglutaminase during tumour growth and metastasis. Carcinogenesis 1985, 6:459-463. 10.1093/carcin/6.3.459, 2858274.
31. Fesus L, Thomazy V, Falus A. Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett 1987, 224:104-108. 10.1016/0014-5793(87)80430-1, 2890537.
32. Yuan L, Behdad A, Siegel M, Khosla C, Higashikubo R, Rich KM. Tissue transgluaminase 2 expression in meningiomas. J Neurooncol 2008, 90:125-132. 10.1007/s11060-008-9642-1, 18587533.
33. Mian S. el Alaoui S, Lawry J, Gentile V, Davies PJ, Griffin M: The importance of the GTP-binding protein tissue transglutaminase in the regulation of cell cycle progression. FEBS Lett 1995, 370:27-31. 10.1016/0014-5793(95)00782-5, 7649299.
34. Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K, Kirshenbaum LA, Gibson SB. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 2003, 22:4734-4744. 10.1038/sj.onc.1206666, 12879018.
35. Kennedy AS, Harrison GH, Mansfield CM, Zhou XJ, Xu JF, Balcer-Kubiczek EK. Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: effect of TP53 or hMLH1 deficiency. Int J Cancer 2000, 90:175-185. 10.1002/1097-0215(20000820)90:4<175::AID-IJC1>3.0.CO;2-W, 10993958.
36. Baetz D, Regula KM, Ens K, Shaw J, Kothari S, Yurkova N, Kirshenbaum LA. Nuclear factor-kappaB-mediated cell survival involves transcriptional silencing of the mitochondrial death gene BNIP3 in ventricular myocytes. Circulation 2005, 112:3777-3785. 10.1161/CIRCULATIONAHA.105.573899, 16344406.